Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.

Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stussi G, Zucca E, Stathis A, Sloss CM, Bertoni F.

Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7.

2.

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J.

Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.

3.

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.

Hicks SW, Lai KC, Gavrilescu LC, Yi Y, Sikka S, Shah P, Kelly ME, Lee J, Lanieri L, Ponte JF, Sloss CM, Romanelli A.

Neoplasia. 2017 Sep;19(9):661-671. doi: 10.1016/j.neo.2017.06.001. Epub 2017 Jul 25.

4.

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB.

Mol Cancer Ther. 2015 Jul;14(7):1625-36. doi: 10.1158/1535-7163.MCT-14-0772. Epub 2015 Apr 24.

5.

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA.

Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. Review.

6.

MAP kinase phosphatase-2 plays a critical role in response to infection by Leishmania mexicana.

Al-Mutairi MS, Cadalbert LC, McGachy HA, Shweash M, Schroeder J, Kurnik M, Sloss CM, Bryant CE, Alexander J, Plevin R.

PLoS Pathog. 2010 Nov 11;6(11):e1001192. doi: 10.1371/journal.ppat.1001192.

7.

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA.

Cancer Res. 2010 Jul 1;70(13):5213-9. doi: 10.1158/0008-5472.CAN-10-0118. Epub 2010 Jun 15.

8.

Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cells.

Sloss CM, Wang F, Palladino MA, Cusack JC Jr.

Oncogene. 2010 May 27;29(21):3146-52. doi: 10.1038/onc.2010.52. Epub 2010 Mar 8.

9.

Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2.

Cadalbert LC, Sloss CM, Cunningham MR, Al-Mutairi M, McIntire A, Shipley J, Plevin R.

Cell Signal. 2010 Mar;22(3):357-65. doi: 10.1016/j.cellsig.2009.10.002.

PMID:
19843478
10.

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC Jr.

Clin Cancer Res. 2008 Aug 15;14(16):5116-23. doi: 10.1158/1078-0432.CCR-07-4506.

11.

G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes.

Goon Goh F, Sloss CM, Cunningham MR, Nilsson M, Cadalbert L, Plevin R.

Cell Signal. 2008 Jul;20(7):1267-74. doi: 10.1016/j.cellsig.2008.02.015. Epub 2008 Feb 29.

PMID:
18424071
12.

Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance.

Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack JC.

Oncogene. 2007 Mar 29;26(14):2006-16. Epub 2006 Sep 25.

PMID:
17001310
14.

The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes.

Macfarlane SR, Sloss CM, Cameron P, Kanke T, McKenzie RC, Plevin R.

Br J Pharmacol. 2005 Jun;145(4):535-44.

15.
16.

When street sex workers are mothers.

Sloss CM, Harper GW.

Arch Sex Behav. 2004 Aug;33(4):329-41.

PMID:
15162079

Supplemental Content

Loading ...
Support Center